Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

SCIVAX: biomarcadores de disfunción inmunitaria y respuesta a vacunas en LME crónica (SCIVAX)

2 de noviembre de 2026 actualizado por: Ona Bloom, Northwell Health

Biomarcadores de disfunción inmunitaria y respuesta a vacunas en personas con lesión traumática crónica de la médula espinal

The purpose of this observational research study is to better understand immune responses to vaccines against viruses (influenza or SARS-CoV2). The goal is to determine any differences in immune responses to vaccines in uninjured people and in people living with spinal cord injuries, who are typically at increased risk of infections.

Descripción general del estudio

Descripción detallada

The purpose of this research study is to measure a person's immune response to a vaccine by measuring types of circulating white blood cells (WBC) and the substances they produce in blood, including antibodies, proteins, and ribonucleic acids (the body's genetic blueprint for making proteins).

The research will study two populations: uninjured people and people living with spinal cord injury (SCI), who are often at increased risk of infections. We will measure and observe over time any differences in immune responses to vaccines between those groups or among people with SCI according to their injury severity or level.

The overall goal of this study is to increase knowledge of immune responses to vaccination against influenza virus that causes the flu, and to the SARS-CoV-2 virus that causes COVID-19. There is currently a lack of information about what influences individual responses to vaccines and why people with SCI are at typically at increased risk of infection. Results from this study may teach us how to improve vaccination strategies and other ways to fight infections in uninjured people and in people with SCI

Tipo de estudio

De observación

Inscripción (Estimado)

140

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • New York
      • Manhasset, New York, Estados Unidos, 11030
        • Northwell Health

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 89 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Participants will be adults (ages 18-89 years old) with SCI or who are uninjured controls who are electing to receiving flu or COVID-19 vaccines to promote their health.

Descripción

Inclusion Criteria

SCI Participant Inclusion Criteria: To be eligible for prospective enrollment, participants are required to meet the following inclusion criteria:

  • 18-89 years old with traumatic SCI
  • initial traumatic SCI >/=1 year from enrollment (DOD funded study)
  • initial traumatic SCI <1 year from enrollment (non-DOD funded pilot study)
  • American Spinal Injury Association (ASIA) classification grade A-D
  • Neurological Injury Level C1-T10
  • Demonstrate capacity to provide informed consent using the "teach back" method to verify understanding and appreciation of study objectives and procedures.

Exclusion Criteria

To be eligible for prospective enrollment, SCI participants are required to not meet the following exclusion criteria:

  • Stage III-IV pressure ulcers
  • Cancer, chemotherapy, neutropenia
  • Pregnancy or lactation
  • No known SCI
  • Autoimmune disease
  • Pre-existing neurological disease
  • History of dementia
  • Any other condition that would compromise their ability to provide informed consent
  • Any other condition that a study physician feels would preclude participation or be contraindicated

Uninjured Control Group:

Inclusion Criteria

Uninjured Control Participant Inclusion Criteria: To be eligible for prospective enrollment, participants are required to meet the following inclusion criteria:

  • 18-89 years old without traumatic SCI
  • Demonstrate capacity to provide informed consent using the "teach back" method to verify understanding and appreciation of study objectives and procedures.

Exclusion Criteria

To be eligible for prospective enrollment, uninjured control participants are required to not meet the following exclusion criteria:

  • Cancer, chemotherapy, neutropenia
  • Pregnancy or lactation
  • Autoimmune disease
  • Pre-existing neurological disease
  • History of dementia
  • Any other condition that would compromise their ability to provide informed consent
  • Any other condition that a study physician feels would preclude participation or be contraindicated

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Individuals with Chronic Spinal Cord Injury who receive either Flu or COVID-19 vaccine

18-89 years old with traumatic SCI, AIS grade A-D, Neurological injury level of C1-T10 who are choosing to receive a vaccine against the flu or COVID-19 and demonstrate capacity to provide informed consent.

Uninjured Controls who receive the Flu vaccine or COVID-19 vaccine

18-89 years old without traumatic Spinal Cord Injury (SCI) who are choosing to receive a vaccine against either the Flu or COVID-19 and demonstrate the capacity to provide informed consent.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
mRNA transcript levels for genes expressed according to white blood cell type after flu vaccination
Periodo de tiempo: 0-28 days after flu vaccination

Serum samples will be used to determine if gene expression levels made by specific types of white blood cells are different between participant groups and within the SCI group by injury level and severity.

0-28 days after flu vaccination
Anti-flu antibody titers in response to vaccination
Periodo de tiempo: 0-28 days after flu vaccination

Serum samples will be used to determine antibody titers for anti-flu antibodies at baseline and after vaccination. These samples will be obtained to determine if vaccine responses are different between participant groups and within the SCI group by injury level and severity

0-28 days after flu vaccination

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
mRNA transcript levels for genes expressed according to white blood cell type after COVID-19 vaccination
Periodo de tiempo: 0-28 days after COVID-19 vaccination

Serum samples will be used to determine if gene expression levels made by specific types of white blood cells are different between participant groups and within the SCI group by injury level and severity.

0-28 days after COVID-19 vaccination
Anti-COVID-19 antibody titers in response to vaccination
Periodo de tiempo: 0-28 days after COVID-19 vaccination

Serum samples will be used to determine antibody titers for anti-COVID-19 antibodies at baseline and after vaccination. These samples will be obtained to determine if vaccine responses are different between participant groups and within the SCI group by injury level and severity

0-28 days after COVID-19 vaccination
Systemic inflammatory cytokine levels in response to vaccination
Periodo de tiempo: 0-28 days after vaccination

Serum samples will be used to determine systemic inflammatory cytokine levels at baseline and after flu or COVID-19 vaccination. These samples will be obtained to determine if cytokine levels are different between participant groups and within the SCI group by injury level and severity

0-28 days after vaccination

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Ona Bloom, PhD, Feinstein Institute for Medical Research; Northwell Health

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

31 de marzo de 2023

Finalización primaria (Actual)

30 de septiembre de 2026

Finalización del estudio (Estimado)

31 de diciembre de 2027

Fechas de registro del estudio

Enviado por primera vez

10 de mayo de 2023

Primero enviado que cumplió con los criterios de control de calidad

19 de mayo de 2023

Publicado por primera vez (Actual)

23 de mayo de 2023

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

4 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Última verificación

1 de marzo de 2026

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir